CI
TEVA icon

Clal Insurance’s Teva Pharmaceuticals TEVA Stock Holding History

Clal Insurance’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.15B Buy
38,446,506
+1,042,400
+3% +$33.5M 6.91% 4
2025
Q4 		$1.17B Buy
37,404,106
+5,917,423
+19% +$146M 7.56% 3
2025
Q3 		$633M Sell
31,486,683
-876,000
-3% -$15.4M 4.83% 4
2025
Q2 		$543M Sell
32,362,683
-5,431,385
-14% -$87.6M 5.34% 4
2025
Q1 		$578M Sell
37,794,068
-1,168,705
-3% -$20.9M 5.98% 3
2024
Q4 		$860M Buy
38,962,773
+4,418,961
+13% +$80.4M 7.75% 3
2024
Q3 		$621M Buy
34,543,812
+2,204,623
+7% +$38.6M 5.5% 4
2024
Q2 		$526M Buy
32,339,189
+3,544,823
+12% +$54.6M 5.5% 3
2024
Q1 		$406M Sell
28,794,366
-4,009,765
-12% -$50.5M 4.57% 6
2023
Q4 		$343M Buy
32,804,131
+2,189,462
+7% +$20.4M 4.49% 4
2023
Q3 		$312M Sell
30,614,669
-1,000,000
-3% -$9.31M 4.35% 5
2023
Q2 		$238M Buy
31,614,669
+12,779,003
+68% +$104M 2.85% 7
2023
Q1 		$161M Buy
18,835,666
+406,000
+2% +$4.01M 2.42% 13
2022
Q4 		$169M Sell
18,429,666
-977,100
-5% -$8.53M 2.53% 11
2022
Q3 		$155M Buy
19,406,766
+444,000
+2% +$3.93M 2.13% 11
2022
Q2 		$138M Buy
18,962,766
+1,424,200
+8% +$12.4M 1.84% 15
2022
Q1 		$168M Hold
17,538,566
– – 1.77% 15
2021
Q4 		$138M Sell
17,538,566
-120,000
-0.7% -$1.08M 1.5% 18
2021
Q3 		$172M Buy
17,658,566
+1,824,764
+12% +$17.1M 1.96% 13
2021
Q2 		$157M Buy
15,833,802
+1,428,610
+10% +$15.1M 1.79% 13
2021
Q1 		$166M Sell
14,405,192
-170,000
-1% -$1.95M 1.92% 10
2020
Q4 		$131M Buy
14,575,192
+665,747
+5% +$6.38M 1.79% 17
2020
Q3 		$125M Sell
13,909,445
-2,509,126
-15% -$26.5M 2.11% 14
2020
Q2 		$202M Buy
16,418,571
+3,105,000
+23% +$35.1M 4.01% 1
2020
Q1 		$120M Buy
13,313,571
+13,265,242
+27,448% +$136M 2.99% 6
2019
Q4 		$4.93M Sell
48,329
-2,553,242
-98% -$22.8M 5.29% 4
2019
Q3 		$17.9M Hold
2,601,571
– – 0.44% 57
2019
Q2 		$24M Sell
2,601,571
-485,695
-16% -$5.86M 0.55% 46
2019
Q1 		$48.4M Sell
3,087,266
-695,030
-18% -$12.3M 1.19% 31
2018
Q4 		$58.3M Buy
3,782,296
+1,968,077
+108% +$40.3M 1.52% 20
2018
Q3 		$39.1M Buy
1,814,219
+1,138,423
+168% +$26.4M 1.04% 27
2018
Q2 		$16.4M Buy
675,796
+51,364
+8% +$1.05M 0.43% 33
2018
Q1 		$10.7M Sell
624,432
-900,000
-59% -$17.6M 0.28% 36
2017
Q4 		$28.9M Sell
1,524,432
-1,554,248
-50% -$23.4M 0.76% 26
2017
Q3 		$54.2M Buy
3,078,680
+88,151
+3% +$1.98M 1.31% 24
2017
Q2 		$99.3M Buy
2,990,529
+1,282,527
+75% +$39.7M 1.98% 11
2017
Q1 		$54.8M Sell
1,708,002
-168,096
-9% -$5.74M 1.12% 18
2016
Q4 		$68M Sell
1,876,098
-1,301,550
-41% -$52M 1.27% 13
2016
Q3 		$146M Sell
3,177,648
-19,253
-0.6% -$1M 3.3% 5
2016
Q2 		$161M Sell
3,196,901
-1,285,900
-29% -$68.5M 4.08% 6
2016
Q1 		$240M Buy
4,482,801
+292,860
+7% +$17.2M 6.99% 1
2015
Q4 		$275M Sell
4,189,941
-171,256
-4% -$10.6M 7.36% 1
2015
Q3 		$246M Buy
4,361,197
+81,395
+2% +$5.28M 6.39% 2
2015
Q2 		$253M Buy
4,279,802
+192,272
+5% +$11.9M 5.82% 2
2015
Q1 		$255M Sell
4,087,530
-368,133
-8% -$21.4M 5.87% 3
2014
Q4 		$256M Buy
+4,455,663
New +$248M 6.12% 2

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Clal Insurance's TEVA Position: Q1 2026 in Review

Clal Insurance increased its Teva Pharmaceuticals (TEVA) stake by 2.8% in Q1 2026, buying an estimated $33.5M and bringing the position to 38,446,506 shares worth $1.15B. The position accounts for 6.91% of the portfolio, ranked #4.

Clal Insurance first reported a position in TEVA in Q4 2014 and has held it in 46 quarters since. The position peaked at $1.17B in Q4 2025. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Clal Insurance held 38,446,506 shares of Teva Pharmaceuticals worth $1.15B as of Q1 2026.
  • Clal Insurance bought 1,042,400 Teva Pharmaceuticals shares in Q1 2026, an estimated $33.5M.
  • Teva Pharmaceuticals made up 6.91% of Clal Insurance's portfolio in Q1 2026, its #4 holding.
  • Clal Insurance first reported a position in Teva Pharmaceuticals in Q4 2014 and has held it in 46 quarters since.
  • Clal Insurance's Teva Pharmaceuticals position peaked at $1.17B in Q4 2025.
  • 650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Clal Insurance's 13F filing for Q1 2026, filed 12 May 2026.